English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ✅ Growth passed
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 45.00%
Price change 2019 → 2020: 35.01%
Price change 2020 → 2021: -11.59%
Price change 2021 → 2022: -18.22%
Price change 2022 → 2023: -27.17%
Price change 2023 → 2024: -10.26%
Price change 2024 → 2025: -0.21%
Price change 2025 → 2026: -23.58%
Price change 2026 (year to date): -23.10%
Financial growth
Revenue CAGR (8 years): 5.31%
Earnings CAGR (8 years): 43.81%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 2.28
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 19.93
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 33.19% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="BLC.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Bastide Le Confort Médical S.A. | 19.6 | 5.70 | +10.3 % | 🔒 |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Euroapi S.A. | – | 0.08 | −1.3 % | – |
| Guerbet S.A. | – | 1.64 | +5.5 % | – |
| LNA Santé S.A. | 9.5 | 2.75 | +10.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Bastide Le Confort Médical S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2021 | 495 m | 15.0 m | 3.0 % | n/a |
| 2022 | 522 m | 15.3 m | 2.9 % | +5.5 % |
| 2023 | 566 m | 13.4 m | 2.4 % | +8.5 % |
| 2024 | 591 m | -1.0 m | -0.2 % | +4.3 % |
| 2025 | 548 m | 588,646 | 0.1 % | -7.3 % |
| 2026 | 538 m | 64.8 m | 12.0 % | -1.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Bastide Le Confort Médical S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 22.1 m | 36.7 m | 23.6 m | 25.5 m | 48.2 m |
| Total Debt | 419 m | 427 m | 409 m | 411 m | 299 m |
| Net Debt | 397 m | 391 m | 385 m | 386 m | 251 m |
| Equity | 84.6 m | 87.6 m | 79.8 m | 72.1 m | 131 m |
| Total assets | 633 m | 657 m | 647 m | 661 m | 576 m |
| Operating cash flow | 56.9 m | 106 m | 66.0 m | 71.9 m | 81.8 m |
| Investments (capex) | 53.3 m | 53.6 m | 55.4 m | 60.1 m | 51.0 m |
| Free cash-flow | -6.5 m | 36.6 m | 10.6 m | 41.7 m | 30.8 m |
| Share buybacks | 240,000 | 0 | 0 | 4,000 | 6,000 |
| Dividends paid | 2.2 m | 613,000 | 1.6 m | 569,000 | 554,000 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Bastide Le Confort Médical S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Bastide Le Confort Médical S.A. | 161 m | 21.5 | 0.1 % |
| Guerbet S.A. GBT.PA | 90.2 m | n/a | -13.8 % |
| Transgene S.A. TNG.PA | 232 m | n/a | -7,658.0 % |
| Genfit S.A. GNFT.PA | 591 m | n/a | -131.4 % |
| Adocia S.A. ADOC.PA | 67.3 m | n/a | -1,124.8 % |
| Innate Pharma S.A. IPH.PA | 156 m | n/a | -1,764.5 % |
| Cellectis S.A. ALCLS.PA | 81.0 m | n/a | -92.7 % |
| LNA Santé S.A. LNA.PA | 303 m | 10.7 | 2.6 % |
| ABIONYX Pharma S.A. ABNX.PA | 75.7 m | n/a | -136.6 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Bastide Le Confort Médical S.A.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 07/01/2022 | 0.270 EUR | 11/01/2022 |
| 07/01/2021 | 0.270 EUR | 11/01/2021 |
| 07/12/2018 | 0.260 EUR | 03/01/2019 |
| 18/12/2017 | 0.260 EUR | 20/12/2017 |
| 15/12/2016 | 0.260 EUR | 19/12/2016 |
| 15/12/2015 | 0.250 EUR | 17/12/2015 |
| 15/12/2014 | 0.220 EUR | 17/12/2014 |
| 12/12/2013 | 0.190 EUR | 17/12/2013 |
Stock splits
| Date | Operation |
|---|---|
| 19/12/2007 | split: 3 shares for 1 |
| 29/12/2005 | split: 3 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Bastide Le Confort Médical S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Bastide Le Confort Médical S.A.
What is the Bastide Le Confort Médical S.A. share price?
Latest recorded price: 19.78 EUR on 06/11/2026, for a market cap of 161 m USD.
What is the revenue of Bastide Le Confort Médical S.A.?
538 m USD for fiscal year 2026, with net income of 64.8 m USD (net margin 12.0 %).
Does Bastide Le Confort Médical S.A. pay a dividend?
Yes. Latest dividend: 0.270 EUR per share, ex-dividend on 07/01/2022. Over 12 months: 0.0000 EUR. Yield on the latest known price: 0.2 %.
What is the P/E ratio of Bastide Le Confort Médical S.A.?
Trailing 12-month P/E of 21.5.
Is Bastide Le Confort Médical S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0000035370) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Bastide Le Confort Médical S.A. have?
3,635 full-time employees according to the latest published profile.
Who runs Bastide Le Confort Médical S.A.?
Vincent Bastide is the company's chief executive.